FDA CDER regulatory intelligence for biotech analysts.
Biotech analysts at small healthcare-focused funds need every FDA approval, every CRL, every advisory committee outcome — within minutes of publication, not days. A two-person investment team cannot afford a Clarivate Cortellis subscription at $15,000 per year per seat. Cresthaven Analytics delivers FDA CDER, CBER, CDRH, EMA, MHRA, and 75 other agencies as structured briefs from $149 per month.
What FDA CDER does
The FDA Center for Drug Evaluation and Research approves and regulates new and generic drugs in the United States — small-molecule pharmaceuticals, over-the-counter products, and most prescription medications. CDER publishes approval letters, complete response letters (CRLs), advisory committee briefing books, REMS modifications, label changes, safety communications, and guidance documents on an ongoing basis. For biotech investors, pharma operators, and any analyst tracking drug-development pipelines, CDER actions move both individual stocks and the broader sector within minutes of publication.
Why biotech analysts need FDA CDER intelligence
For a biotech analyst at a $200 million fund with a two-person investment team, every FDA CDER decision moves the relevant stock and frequently the broader sector. PDUFA dates, advisory committee outcomes, CRLs, and label expansions are all alpha events you need within minutes of publication, not days. Clarivate Cortellis starts at $15,000 per year per seat. Pink Sheet adds another $3,000-8,000. Cresthaven Analytics delivers the same regulatory event coverage in structured executive briefs from $149 per month — with the strategic delta analysis you need to brief your PM the same morning.
Recent FDA CDER brief from Cresthaven
June 24, 2026
DEA issues notice of intent to temporarily place O-desmethyltramadol in Schedule I of the Controlled Substances Act
The DEA published a notice of intent on June 24, 2026 to place O-desmethyltramadol (O-DSMT) in Schedule I on a temporary basis. The forthcoming order imposes full Schedule I controls and criminal, civil, and administrative sanctions on all persons who handle the substance.
Read the full brief →Recommended tier for biotech analysts
Executive ($999/month)
Up to 30 agencies covers the full healthcare regulatory universe (all three FDA centers, EMA, MHRA, EU SANTE, PMDA, TGA, HSA, plus CMS for reimbursement) with priority alerts for material developments. For an analyst at a smaller fund, Professional at $399/month covers 6 agencies — pick the three FDA centers plus EMA, MHRA, CMS.
View all tiers →Frequently asked
Does Cresthaven Analytics cover FDA CDER advisory committee outcomes and PDUFA decisions?
Yes. The Atlas pipeline runs a dedicated FDA Drug Regulation vertical covering CDER actions including NDA and ANDA approvals, CRLs, advisory committee briefing books and outcomes, REMS modifications, label changes, safety communications, and guidance documents. Material approvals are delivered as structured briefs within minutes of FDA publication.
How does Cresthaven compare to Clarivate Cortellis or Citeline Pink Sheet for FDA tracking?
Clarivate Cortellis and Citeline Pink Sheet are deep-database products: structured regulatory records, decades-long historical archives, often priced $15,000 to $40,000 per year for small-team licenses. Cresthaven Analytics is a focused brief-delivery service at $149 to $999 per month. Cresthaven covers what changed today and what it means; Cortellis and Pink Sheet are the right choice if you need a deep searchable historical database.
What is the cheapest Cresthaven tier for a small biotech fund covering CDER plus other FDA centers?
Basic at $149 per month covers 3 agencies — a typical pharma-focused setup is FDA CDER + FDA CBER + EMA for cross-jurisdictional drug coverage. Add FDA CDRH for medical-device coverage, MHRA for UK exposure, or CMS for reimbursement intelligence at $29 per month each. For a broader pharma plus device universe, Professional at $399 per month covers 6 agencies.
Does Cresthaven flag CDER policy shifts (e.g. accelerated approval reform) separately from individual drug approvals?
Yes. The materiality triage distinguishes individual approval events (one drug, one decision) from policy-level shifts (accelerated approval reform, expedited program evolution, new guidance frameworks). Policy briefs include forward implications for affected sponsors, indications, and therapeutic areas.